Structure Therapeutics

GPCR

Market cap $4.22B

Casdin Capital sold 380,000 shares of Structure Therapeutics in the fourth quarter for an estimated $15.52 million. Meanwhile, the quarter-end position value actually increased by $38.18 million, reflecting both trading and market price movement as shares soared in the period.

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks

Hedge fund BVF increased its GPCR holding by 275,105 shares in the fourth quarter; the estimated trade value was $11.2 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $152.3 million, reflecting both stock price changes and trading activity.

Structure Therapeutics Inc. has evolved from a “dark horse” to a leading contender in the oral GLP-1 obesity drug market. GPCR's market cap surged from $1.3B to $5B in five months, reflecting heightened investor confidence after a successful Phase II readout and improved competitive positioning. The weight-loss drug market has shifted to mass-market pricing, with cash options as low as $149/month, broadening patient access.

Structure Therapeutics' GLP-1 drug candidate, aleniglipron, has helped people lose up to 15% of their body weight. Its share price has tripled in the past year, suggesting investors have already priced approval into its valuation.

Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.

Ray Stevens, Structure CEO, joins 'Fast Money' to talk its weigh-loss drug pipeline, potential M&A, and more.

In early December, over 50,000 shares of Structure Therapeutics were indirectly sold by a stakeholding company, valued at nearly $4 million. The stakeholding company is predominantly controlled by the Johnson family, who are highly active in the pharmaceutical sector.

Structure Therapeutics' positive phase 2 data for aleniglipron sent its stock price soaring last year. The medicine could join the fast-growing weight loss market, but it will face plenty of competition.